Novartis gets breakthrough designation for Xolair successor, setting up spotlight for PhIII readout later this year
With its Roche-partnered Xolair no longer under patent protection, Novartis and CEO Vas Narasimhan are looking for the next drug up to step into the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
